Table 2.
Characteristics of statins studies.
| Study | n (M/F) | Age (year) | BMI (kg/m2) | Cardiovascular disease risk | Treatment duration (week) | Statin | Daily dose (mg) | Fat-meal content (%) | Fat-meal energy (kcal) |
|---|---|---|---|---|---|---|---|---|---|
| Simo et al. (1993)8 | 11M | 42 ± 7 | 26 ± 3 | Dyslipidemic | 6 | Lovastatin | 40 | 69 | n.a. |
| Contacos et al. (1998)28 | 12M/7F | 56 ± 12 | 27 ± 5 | MetS | 6 | Pravastatin | 40 | 90 | n.a. |
| Battula et al. (2000)30 | 2M/6F | 67 ± 11 | 29 ± 3 | Dyslipidemic, T2DM | 4 | Cerivastatin | 0.3 | 55 | 1100 |
| Twickler et al. (2000)29 | 4M/3F | 47 ± 7 | 26 ± 2 | FCHL | 16 | Simvastatin | 80 | 40 | n.a. |
| Sheu et al. (2001)31 | 8M/16F | 62 ± 10 | 26 ± 4 | MetS | 16 | Simvastatin | 20 | 33 | 2190 |
| Wilmink et al. (2001)32 | 15M | 25 ± 4 | 22 ± 3 | Hypertense | 3 | Cerivastatin | 0.4 | 40 | n.a. |
| Dane-Stewart et al. (2002)33 | 15M/3F | n.a. | 27 ± 6 | CHD, overweight | 12 | Atorvastatin | 80 | 47 | 437 |
| Guerin et al. (2002)34 | 11M | 55 ± 10 | 27 ± 3 | Overweight, dyslipidemic | 6 | Atorvastatin | 40 | 48 | 1200 |
| Schaefer et al. (2002)36 | 74M/14F | 62 ± 9 | 28 ± 3 | CHD, overweight, dyslipidemic | 4 | Atorvastatin | 40 | 57 | 880 |
| Parhofer et al. (2003)12 | 8M/2F | 40 ± 9 | 27 ± 3 | MetS | 4 | Atorvastatin | 10 | 87 | 1305 |
| Verseyden et al. (2003)37 | 6M/6F | 43 ± 17 | 26 ± 2 | FCHL, MetS | 12 | Atorvastatin | 80 | n.a. | n.a. |
| Castro Cabezas et al. (2004)38 | 10M/8F | 45 ± 8 | 26 ± 2 | FCHL, MetS | 16 | Atorvastatin | 80 | n.a. | n.a. |
| van Wijk et al. (2005)39 | 12M/6F | 49 ± 6 | 24 ± 4 | PTCA | 5 | Simvastatin | 80 | 40 | n.a. |
| Olijhoek et al. (2008)40 | 19M | 54 ± 7 | 30 ± 3 | MetS | 6 | Simvastatin | 80 | 40 | 925 max |
| Arao et al. (2009)35 | 16M | 63 ± 8 | 23 ± 3 | CHD, dyslipidemic | 24 | Pitavastatin | 2 | 33 | 680 |
| Hajer et al. (2009)41 | 19M | 54 ± 7 | 30 ± 3 | MetS | 6 | Simvastatin | 80 | 40 | 925 max |
| Nagashima et al. (2011)43 | 12M | 48 ± 9 | 28 ± 3 | MetS | 2 | Pitavastatin | 2 | 35 | 342 |
| Lee et al. (2012)42 | 10M/18F | 63 ± 8 | 26 ± 2 | Dyslipidemic | 8 | Atorvastatin | 20 | 30 | 750 |
| Mora-Rodriguez et al. (2020)13 | 9M/1F | 61 ± 7 | 30 ± 4 | MetS | 1 | Various | – | 36 | 995 |
| Alvarez-Jimenez et al. (2021)14 | 7M/1F | 61 ± 7 | 30 ± 4 | MetS | 1 | Various | – | 38 | 862 |
Note: Data are expressed as mean ± SD.
Abbreviations: BMI = body mass index; CHD = coronary artery disease; F = female; FCHL = familiar hypercholesterolemia; M = male; MetS = metabolic syndrome; n.a. = not available; PTCA = percutaneous transluminal coronary angioplasty; T2DM = type 2 diabetes mellitus.